CAR-X™ Solution

Detect. Enrich. Engineer.

A complete product line for CAR detection, CAR+ cell enrichment and lentiviral engineering, with a Cat No for every product.

CAR-X™ Solution spans four stages of CAR research: isolation of starting immune cells, lentiviral engineering of the CAR, detection of CAR expression, and enrichment of CAR+ cells with downstream phenotypic analysis. Product formats include flow cytometry antibodies, nanobeads, indirect isolation kits, ELISA kits, recombinant cytokines and premade lentiviral particles, supporting method development, process development and functional evaluation of CAR-T and CAR-NK products.

Three modules of the CAR-X™ Solution

01 | DETECT

CAR Detection & Cell Characterization

Determine the level of CAR expression, the subsets in which CAR is expressed, the functional state of the cells, and the amount of soluble CAR released.

  • CAR detection antibodies (flow cytometry): Anti-G4S Linker, Anti-Whitlow (218) Linker, Anti-VHH and Anti-FMC63 (anti-idiotype); PE / FITC / APC / Biotin conjugates
  • Soluble CAR ELISA: CD19, CD20, HER2, BCMA and GPC3, 96 T format
  • Immune cell characterization antibodies: six panels
  • Cytokine ELISA: IL-2, IFN-γ, IL-6 and TNF-α, 96 T format

Explore detection tools

02 | ENRICH

CAR⁺ Cell Enrichment & Assay Development

Separate CAR+ cells from a heterogeneous transduced population and provide the reagents required for starting cell isolation and expansion.

  • CAR+ enrichment nanobeads: Anti-G4S Linker, Anti-Whitlow (218) Linker and Anti-VHH, direct method
  • Indirect isolation kits: Column-based and Column-free as separate Cat Nos
  • SOLIDEX®-ISOEx starting cell isolation: Pan-T, CD4+ T, CD8+ T, NK and Classical Monocyte, untouched negative selection
  • Anti-TAA antibodies and recombinant cytokines for assay development

Explore enrichment tools

03 | ENGINEER

CAR Lentiviral Engineering

Ready-to-use premade CAR lentiviral particles that replace construct building and virus packaging.

  • Good Validated Premade Lenti-CAR Particles: CD19, CD20, HER2, BCMA and GPC3
  • Three components per particle: Cargo (CAR construct), Fusogen (VSV-G / Cocal variants) and Binder (CD3 / CD7)
  • Start at transduction instead of vector construction, cloning, packaging and titre determination
  • Suitable for method development, positive controls and rapid start-up on standard targets

Explore premade particles

Matching detection and enrichment tools to CAR construct structure

CAR detection antibodies and enrichment nanobeads recognize the structure of the construct, not the target. The first step in selection is to confirm whether the construct contains a G4S, Whitlow (218) or VHH sequence; if the recognition element does not match, the result is not valid.

Construct featureDetection antibodyEnrichment nanobeadsIndirect isolation kit
Contains G4S LinkerAnti-G4S Linker mAbAnti-G4S Linker Nanobeads (Column-Based)SOLIDEX®-ISOEx Indirect Anti-G4S Linker Isolation Kit (Column-based / Column-free)
Contains Whitlow (218) LinkerAnti-Whitlow (218) Linker mAbAnti-Whitlow (218) Linker Nanobeads (Column-Based)SOLIDEX®-ISOEx Indirect Anti-Whitlow (218) Isolation Kit (Column-based / Column-free)
Contains VHH / NanobodyAnti-VHH mAbAnti-VHH Nanobeads (Column-Based)SOLIDEX®-ISOEx Indirect Anti-VHH Isolation Kit (Column-based / Column-free)
FMC63-derived scFvAnti-FMC63 mAb (anti-idiotype)/Detect via the anti-idiotype route; enrichment assessed per project

Trade-off between the two routes: anti-linker reagents are broadly applicable but require a standard linker in the construct; anti-idiotype reagents are highly specific but cover a single scFv. When the construct is not fully characterized, start with anti-linker detection and confirm with anti-idiotype.

CAR research workflow

StepStageActionMatching products
Step 1PBMC isolationFicoll density-gradient separation of PBMC as starting materialGeneral consumables, no matching product
Step 2Starting immune cell isolationUntouched negative selection for Pan-T / CD4 / CD8 / NKSOLIDEX®-ISOEx Isolation Kits
Step 3Cell activationCD3/CD28 stimulation with IL-2 to drive cells into cycleRecombinant IL-2
Step 4CAR lentiviral transductionTransduction with premade CAR particlesPremade Lenti-CAR Particles
Step 5ExpansionIL-2 / IL-7 / IL-15 / IL-21 support expansion to the required cell numberRecombinant Cytokines
Step 6CAR expression detectionFlow cytometry for positivity and phenotype of positive cells; supernatant for shed CARCAR Detection Antibodies; Soluble CAR ELISA
Step 7CAR+ cell enrichment (optional)Raise the CAR+ fraction and obtain an effector population of defined compositionNanobeads or Indirect Isolation Kits
Step 8Immune phenotyping and functional analysisSubsets, activation, exhaustion, degranulation, cytokine releaseImmune Cell Characterization Antibodies + Cytokine ELISA
In parallelTarget antigen confirmationConfirm target expression on model cells or clinical samplesAnti-TAA Antibodies

Note: the workflow illustrates how products map to research stages and is not a fixed SOP. Whether enrichment is needed depends on the research question, CAR positivity and downstream assay design.

Outside the scope of these products: release QC (sterility, mycoplasma, endotoxin, vector copy number, RCL) and clinical-grade manufacturing. CAR-X products are for research use only (RUO).

FAQ

1Can CAR be detected without a flow cytometer?

Soluble CAR ELISA quantifies shed CAR in the supernatant, but does not provide a positivity rate.

2Can two antibodies be used on the same sample?

Yes, provided the two epitopes do not overlap (linker and idiotype usually do not) and the fluorochromes are distinguishable.

3Does enrichment mask the CAR epitope?

The direct method occupies part of the epitope. If the same antibody is needed for detection after enrichment, use the indirect method.

4Can premade lentivirus be customised for other targets?

Quoted per project; catalogue products are CD19, CD20, HER2, BCMA and GPC3.

5Are anti-linker and anti-idiotype interchangeable?

No. The former recognizes a linker sequence and remains valid after the scFv is changed; the latter recognizes the idiotype of a specific scFv and covers one CAR only.

6Can CAR-X products be used for clinical manufacturing?

Catalogue products are for research use only (RUO); clinical-grade supply is assessed separately.




<